Kong, Sahin, Collins, Wertz, Campbell, Leech, Krueger, Bear, Kunkel, Kohane. Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis. Mol AutismMol AutismMol Autism. 2014;5:16.
NOTES
Kong, Sek WonSahin, MustafaCollins, Christin DWertz, Mary HCampbell, Malcolm GLeech, Jarrett DKrueger, DiljaBear, Mark FKunkel, Louis MKohane, Isaac SengP30 HD018655/HD/NICHD NIH HHS/P50 MH094267/MH/NIMH NIH HHS/England2014/02/26 06:00Mol Autism. 2014 Feb 24;5(1):16. doi: 10.1186/2040-2392-5-16.
Abstract
BACKGROUND: Fragile X syndrome and tuberous sclerosis are genetic syndromes that both have a high rate of comorbidity with autism spectrum disorder (ASD). Several lines of evidence suggest that these two monogenic disorders may converge at a molecular level through the dysfunction of activity-dependent synaptic plasticity. METHODS: To explore the characteristics of transcriptomic changes in these monogenic disorders, we profiled genome-wide gene expression levels in cerebellum and blood from murine models of fragile X syndrome and tuberous sclerosis. RESULTS: Differentially expressed genes and enriched pathways were distinct for the two murine models examined, with the exception of immune response-related pathways. In the cerebellum of the Fmr1 knockout (Fmr1-KO) model, the neuroactive ligand receptor interaction pathway and gene sets associated with synaptic plasticity such as long-term potentiation, gap junction, and axon guidance were the most significantly perturbed pathways. The phosphatidylinositol signaling pathway was significantly dysregulated in both cerebellum and blood of Fmr1-KO mice. In Tsc2 heterozygous (+/-) mice, immune system-related pathways, genes encoding ribosomal proteins, and glycolipid metabolism pathways were significantly changed in both tissues. CONCLUSIONS: Our data suggest that distinct molecular pathways may be involved in ASD with known but different genetic causes and that blood gene expression profiles of Fmr1-KO and Tsc2+/- mice mirror some, but not all, of the perturbed molecular pathways in the brain.
Last updated on 02/25/2023